What Is Mounjaro? A Plain-English Guide to Tirzepatide, How It Works, and Who It's For

Key Takeaways

• Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection FDA-approved in May 2022 for adults with type 2 diabetes.
• It's the first dual agonist approved in the United States, activating two gut hormone receptors (GIP and GLP-1) instead of one.
• In the SURPASS-2 trial, the 15 mg dose lowered A1C by 2.30 percentage points and reduced body weight by 12.4% over 40 weeks.
• The same molecule, when prescribed for obesity rather than diabetes, is sold under the separate brand name Zepbound (FDA-approved November 2023).
• Mounjaro is taken once weekly, on the same day each week, in the abdomen, thigh, or upper arm.
• Common side effects are nausea, diarrhea, decreased appetite, vomiting, and constipation, mostly during dose escalation.

Direct answer (40-60 words)

Mounjaro is the brand name for tirzepatide, a once-weekly injection from Eli Lilly approved by the FDA in May 2022 for adults with type 2 diabetes. It's the first dual GIP and GLP-1 receptor agonist on the U.S. market, lowering blood sugar and producing significant weight loss in published trials.

Table of contents

1. The 30-second answer
2. The active ingredient: tirzepatide
3. How Mounjaro works inside the body
4. What Mounjaro is FDA-approved for (and what it isn't)
5. Mounjaro vs Zepbound: same drug, different label
6. Dosing schedule and the typical titration ladder
7. Clinical trial results: SURPASS-1 through SURPASS-5
8. Side effects and what to expect during the first 8 weeks
9. Who should not take Mounjaro
10. How Mounjaro compares to other GLP-1 medications
11. Cost, insurance, and access in 2026
12. The compounded tirzepatide question
13. FAQ
14. Sources

The active ingredient: tirzepatide

The brand name on the box is Mounjaro. The molecule inside is tirzepatide, a 39-amino-acid synthetic peptide engineered by Eli Lilly to mimic two natural gut hormones at once. Most older diabetes drugs (Ozempic, Trulicity, Victoza) mimic only one. Tirzepatide mimics both, which is why clinicians sometimes call it a "twincretin."

The two hormones it imitates are:

• GIP (glucose-dependent insulinotropic polypeptide). Released by the small intestine after meals, GIP signals the pancreas to release insulin in proportion to how much glucose you've eaten.
• GLP-1 (glucagon-like peptide-1). Also released after meals, GLP-1 stimulates insulin, suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying, and reduces appetite by acting on receptors in the brain.

Activating both pathways simultaneously is what makes tirzepatide more potent than single-agonist drugs in head-to-head comparisons. The FDA approval letter for Mounjaro (May 13, 2022) is the regulatory record of the original approval.

How Mounjaro works inside the body

Tirzepatide does four things at once, which is why it produces results most older drugs can't match.

1. It boosts insulin release after meals (only when blood sugar is high). This is the "glucose-dependent" part. Tirzepatide stimulates the pancreatic beta cells to release insulin, but only in response to elevated blood glucose. When blood sugar is normal, it doesn't push insulin output, which is why the hypoglycemia risk is low compared to insulin or sulfonylureas.

2. It suppresses glucagon. Glucagon is insulin's counterweight, telling the liver to release stored glucose. By dampening glucagon, tirzepatide lowers fasting blood sugar and reduces the liver's contribution to hyperglycemia.

3. It slows gastric emptying. Food stays in the stomach longer, which blunts the post-meal blood sugar spike and produces a sense of fullness that reduces the next meal's portion size. Patients we monitor often describe meals "lasting" much longer than they used to. This is the mechanism behind the appetite reduction.

4. It acts on appetite centers in the brain. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling. Tirzepatide crosses into these centers and reduces the urge to eat, particularly the urge for high-fat, calorie-dense foods, per the Wegovy/STEP-1 satiety mapping work that translates to dual agonists too.

The combined effect is meaningful glucose control and meaningful weight loss from the same once-weekly injection.

What Mounjaro is FDA-approved for (and what it isn't)

Mounjaro has one FDA-approved indication: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. That's it. The label was approved in May 2022.

Mounjaro is not FDA-approved for:

• Weight loss in non-diabetic adults (the same molecule, marketed as Zepbound, is approved for that)
• Type 1 diabetes
• Children or adolescents
• Pregnancy

Despite the narrow label, off-label prescribing for obesity has been common. Clinicians can legally prescribe approved drugs off-label, but insurance coverage and pharmacy availability for off-label Mounjaro have been inconsistent, which is partly why Lilly launched Zepbound as the obesity-labeled version.

Per the FDA Mounjaro prescribing information (current revision), the label still reflects the type 2 diabetes indication only.

Mounjaro vs Zepbound: same drug, different label

This is the single most-confused point about tirzepatide, so it's worth being clear.

The molecule, the dose strengths, the device, and the frequency are identical. The label, the box color, the indication, and the insurance coverage rules are different. Lilly markets them as separate products because U.S. drug approval works on indication-by-indication labeling.

If you're seeing both names in the news, they're the same active drug. If you're paying out of pocket, the price is roughly comparable. If you're using insurance, your coverage may apply to one and not the other depending on your diagnosis.

Dosing schedule and the typical titration ladder

Mounjaro is dosed once weekly on the same day each week. The label requires a slow dose escalation to give the gut time to adapt.

Most patients don't reach 15 mg. The clinical trial protocol used 5, 10, and 15 mg as the three studied maintenance doses. Real-world prescribing often holds at 7.5 or 10 mg if the response is satisfactory.

Each escalation window is roughly 4 weeks. If side effects are intolerable at a given dose, the standard move is to hold at the previous dose for an additional 4 weeks before retrying the escalation. There's no rule that says you must escalate every 4 weeks. The titration is patient-specific.

Clinical trial results: SURPASS-1 through SURPASS-5

The SURPASS program is the set of phase 3 trials that supported FDA approval. Here's what each one showed.

SURPASS-1 (tirzepatide monotherapy, 40 weeks, Rosenstock et al., The Lancet, 202101324-6/fulltext)). In drug-naive type 2 diabetes patients, tirzepatide 5/10/15 mg lowered A1C by 1.87, 1.89, and 2.07 percentage points respectively, vs 0.04 with placebo. Weight loss reached 9.5 kg at 15 mg.

SURPASS-2 (head-to-head vs semaglutide 1 mg, 40 weeks, Frias et al., NEJM, 2021). Tirzepatide 15 mg lowered A1C 2.30 points vs semaglutide's 1.86 points. Weight loss was 11.2 kg vs 5.7 kg. This is the trial that established tirzepatide as more potent than semaglutide for diabetes.

SURPASS-3 (vs insulin degludec, 52 weeks). Tirzepatide produced superior A1C reduction and weight loss compared to titrated basal insulin.

SURPASS-4 (vs insulin glargine in patients with high cardiovascular risk, 104 weeks). Tirzepatide was superior on A1C and showed no excess cardiovascular signal.

SURPASS-5 (added to insulin glargine, 40 weeks). Tirzepatide added on top of insulin produced an additional 2.11-point A1C reduction at 15 mg, with weight loss rather than the weight gain typical of intensified insulin.

The SURMOUNT trials (SURMOUNT-1 through SURMOUNT-4) are the obesity counterpart, and those data drove the Zepbound approval.

Side effects and what to expect during the first 8 weeks

The most common side effects in the SURPASS trials were gastrointestinal:

Most GI symptoms peak in the first 2 to 4 weeks after a dose escalation, then improve. Patients we monitor commonly report that nausea is worst in the 48-hour window after the first 5 mg or 10 mg dose, then fades. Eating smaller meals, avoiding fatty/fried food, and staying hydrated reduces severity for most.

Less common but more serious adverse events include:

• Pancreatitis. The label carries a warning. Severe upper-abdominal pain that radiates to the back warrants immediate evaluation.
• Gallbladder disease. Rapid weight loss increases gallstone risk. Right-upper-quadrant pain after fatty meals warrants imaging.
• Hypoglycemia. Rare with Mounjaro alone, more common when combined with insulin or sulfonylureas. Dose adjustments to those drugs are usually needed.
• Acute kidney injury. Usually secondary to severe vomiting/diarrhea and dehydration. Stay hydrated.
• Hypersensitivity reactions. Rare but reported.
• Diabetic retinopathy progression. Reported with rapid glycemic improvement; baseline retinal exam recommended in patients with known retinopathy.

The boxed warning on the label is for thyroid C-cell tumors based on rodent data. Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Who should not take Mounjaro

Per the FDA label, Mounjaro is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to tirzepatide

Caution and shared decision-making apply for:

• History of pancreatitis
• Severe gastroparesis or other significant GI motility disorders
• Severe renal impairment (especially with persistent vomiting risk)
• Pregnancy and breastfeeding (animal data suggests harm; the label says discontinue at least 2 months before a planned pregnancy)
• Active proliferative diabetic retinopathy
• Type 1 diabetes (the drug isn't studied or approved for this population)

For our drug interaction guide on Mounjaro and oral contraceptives, there's a separate consideration: tirzepatide can reduce the absorption of oral contraceptives during dose escalation, so non-oral contraception (ring, IUD, implant, injection) is recommended for 4 weeks after each escalation.

How Mounjaro compares to other GLP-1 medications

The dual-receptor mechanism is what separates Mounjaro from the rest. Head-to-head, tirzepatide produces larger A1C reductions and larger weight loss than semaglutide at comparable doses, per SURPASS-2.

For deeper comparisons, see our Mounjaro vs Ozempic clinical guide and our tirzepatide vs semaglutide weight-loss comparison.

Cost, insurance, and access in 2026

The retail price of Mounjaro in the U.S. is roughly $1,069 to $1,135 for a one-month supply (four pens) without insurance, depending on the dose strength and pharmacy. With commercial insurance and a covered diagnosis of type 2 diabetes, out-of-pocket cost can range from $25 to a few hundred dollars per month.

Eli Lilly's Mounjaro Savings Card has historically reduced the cost to as low as $25 per month for commercially-insured patients with a type 2 diabetes diagnosis, subject to monthly and annual maximums. Eligibility excludes patients on Medicare, Medicaid, or other federal insurance. Check the Lilly Mounjaro savings program page for current terms.

Patients without diabetes who use Mounjaro off-label for obesity typically don't qualify for the savings card and pay closer to retail. For those patients, Zepbound's separate savings program may apply if they're prescribed Zepbound instead.

For a deeper look at out-of-pocket numbers, see our Mounjaro cost without insurance breakdown.

The compounded tirzepatide question

During the FDA-declared shortage of tirzepatide (which ran from 2022 through October 2024), 503A and 503B compounding pharmacies could legally prepare tirzepatide injections for individual patients. Many telehealth platforms relied on compounded tirzepatide to meet demand.

The FDA removed tirzepatide from the shortage list on October 2, 2024, then reaffirmed that decision in December 2024 after litigation. Compounding pharmacies are now restricted in their ability to prepare bulk tirzepatide, though some still compound personalized formulations under specific clinical justifications (allergy to inactive ingredients, dose strengths not commercially available, etc.).

Compounded tirzepatide is not FDA-approved. It's not the same product as Mounjaro, even though it contains the same active pharmaceutical ingredient. It hasn't undergone the same review process and isn't interchangeable for FDA-approval purposes. Decisions about whether compounded tirzepatide is appropriate for you should be made with a licensed clinician.

For a fuller treatment, see our compounded tirzepatide cost and safety guide.

FAQ

Is Mounjaro the same as Ozempic? No. Mounjaro contains tirzepatide, a dual GIP/GLP-1 agonist. Ozempic contains semaglutide, a single GLP-1 agonist. Both are once-weekly injections approved for type 2 diabetes, but they're different molecules with different potencies. Tirzepatide produced larger A1C and weight reductions than semaglutide in the SURPASS-2 head-to-head trial.

Is Mounjaro approved for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes only. The same molecule, tirzepatide, is approved for chronic weight management under the brand name Zepbound, which Eli Lilly launched in November 2023. Some clinicians prescribe Mounjaro off-label for weight loss, but insurance typically won't cover that use.

How long does it take Mounjaro to work? Blood sugar improvements are usually visible within 2 to 4 weeks. Weight loss typically begins around week 4 to 6 and accelerates over months 3 through 9. Full A1C effect at a stable dose takes about 12 weeks. SURPASS-2 measured outcomes at 40 weeks for the major endpoints.

Can you stop Mounjaro suddenly? You can, but most clinicians prefer a tapered discontinuation when stopping for non-urgent reasons. Stopping abruptly typically causes appetite to return within 2 to 4 weeks and blood sugar to drift back toward pre-treatment levels. Weight regain over 12 months after stopping was substantial in long-term follow-up data from SURPASS and SURMOUNT trials.

What happens if you miss a dose of Mounjaro? If you remember within 4 days of the missed dose, take it and resume your regular weekly schedule. If more than 4 days have passed, skip the missed dose and take the next dose on your usual day. Don't take two doses to make up.

Where do you inject Mounjaro? The abdomen (avoiding 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites week to week to avoid lipohypertrophy. The pen needle is short (4 to 5 mm) and inserts perpendicular to the skin.

Does Mounjaro need to be refrigerated? Yes, before first use. Keep it between 36°F and 46°F (2°C to 8°C). After first use, the pen can be kept at room temperature up to 86°F (30°C) for up to 21 days, then it should be discarded.

Can you drink alcohol on Mounjaro? Moderate alcohol is generally tolerated, but it can worsen nausea and GI side effects, especially during dose escalation. Alcohol also increases hypoglycemia risk if you're also on insulin or a sulfonylurea. Many patients find their alcohol tolerance drops on Mounjaro, sometimes meaningfully.

Is Mounjaro insulin? No. Mounjaro is a GIP/GLP-1 receptor agonist, not insulin. It stimulates your pancreas to release your own insulin in response to meals, which is different from injecting insulin directly. The hypoglycemia risk with Mounjaro alone is low.

How much weight do you lose on Mounjaro? In SURPASS-2 (40 weeks, type 2 diabetes), tirzepatide 15 mg produced 11.2 kg of weight loss on average. In SURMOUNT-1 (72 weeks, obesity without diabetes), tirzepatide 15 mg produced 22.5% body-weight reduction. Real-world weight loss is typically somewhat less than trial averages.

Does Mounjaro cause hair loss? Hair shedding is reported by some patients, usually 3 to 6 months into rapid weight loss. The mechanism is telogen effluvium triggered by rapid weight reduction or caloric restriction, not the drug itself directly. It's typically self-limited and resolves once weight stabilizes.

Can Mounjaro cause cancer? The label carries a boxed warning for thyroid C-cell tumors based on rodent studies. Whether the same risk applies in humans is unclear. Patients with personal or family history of medullary thyroid carcinoma or MEN 2 should not take Mounjaro. Cancer signals haven't appeared in human clinical trial data so far.

Is Mounjaro covered by insurance? Commercial insurance often covers Mounjaro for type 2 diabetes with prior authorization. Coverage for off-label obesity use is rare. Medicare Part D currently doesn't cover GLP-1 medications for weight loss, though it does cover them for diabetes. Medicaid coverage varies by state.

What's the difference between Mounjaro and compounded tirzepatide? Mounjaro is the FDA-approved branded product manufactured by Eli Lilly. Compounded tirzepatide is prepared by a compounding pharmacy in response to an individual prescription. They contain the same active pharmaceutical ingredient but differ in regulatory status, manufacturing oversight, formulation, and price. They are not interchangeable for FDA-approval purposes.

Sources (linked references)

1. Mounjaro FDA approval letter, May 13, 2022.
2. Mounjaro Prescribing Information (FDA label, current revision).
3. Rosenstock J, et al. SURPASS-1: Efficacy and safety of tirzepatide monotherapy in type 2 diabetes. Lancet. 2021;398:143-155.01324-6/fulltext)
4. Frias JP, et al. SURPASS-2: Tirzepatide vs semaglutide for type 2 diabetes. N Engl J Med. 2021;385:503-515.
5. Ludvik B, et al. SURPASS-3: Tirzepatide vs insulin degludec. Lancet. 2021;398:583-598.01443-4/fulltext)
6. Del Prato S, et al. SURPASS-4: Tirzepatide vs insulin glargine in T2D and high CV risk. Lancet. 2021;398:1811-1824.02188-7/fulltext)
7. Dahl D, et al. SURPASS-5: Tirzepatide added to insulin glargine. JAMA. 2022;327:534-545.
8. Jastreboff AM, et al. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
9. Zepbound FDA approval announcement, November 8, 2023.
10. FDA Drug Shortages: Tirzepatide injection resolution announcement, October 2024.
11. American Diabetes Association. Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
12. Lilly Mounjaro Savings Program.
13. American College of Cardiology / AHA Obesity Clinical Practice Guidelines, 2023.
14. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Type 2 Diabetes treatment overview, 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and the KwikPen device are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Trulicity is a registered trademark of Eli Lilly. Victoza, Saxenda, and Byetta are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.